FDA Greenlights Gene Therapy, Because Patience Isn’t a Drug
In a plot twist worthy of a soap opera, the FDA announced it’s 'clearing the way' for Sarepta Therapeutics to resume shipments of their gene therapy for Duchenne muscular dystrophy to some patients. Yes, just some, because apparently miracles come with fine print. The FDA’s official line? They’re 'clearing the way,' which sounds a bit like popping open a space in traffic, except this lane could save lives. Gene therapy shipments resumed, but if you were hoping for a full-on party, well, it’s more of a dignified nod: progress served with a side of bureaucratic seasoning.
Share the Story
FDA finally said 'go' for gene therapy shipments, or as they put it, 'clearing the way.' Someone tell my delivery app to work on that kind of speed. #MiracleMiles
Oh look, FDA is 'clearing the way' for some shipments like it's GPS rerouting around traffic jams. Your gene therapy might arrive sometime between now and the heat death of the universe.
Resuming gene therapy shipments to some patients is like giving only half your friends passes to the Electric Daisy Carnival—exclusive, selective, and sure to cause FOMO.
Source: Statnews | Published: 7/28/2025 | Author: Adam Feuerstein
More Articles in Health
America Adds 50,000 Jobs, But Those 70,000 Stayed Home for Holidays
USS Gerald R. Ford Saves Day By 'Apprehending' Another Wobbly Tanker
Chinese Crackdowns Cut US Fentanyl Supply, Trump Declares Pills Weapons of Mass Destruction
Laura Danger Declares Emotional Labor Is Real Work, Not Invisible Magic
Kennedy’s Protein-Heavy Food Pyramid: Eat More Meat, But Not Saturated Fat, Or Something
Parents Swap 'Because I Said So' For 'Oops, You Bought Too Much Junk'
America Celebrates Lower Gun Deaths While Puffing More Vape Clouds
Trump's Vaccine Makeover: Fewer Shots, More Trust, Same Measles Risks
